LAG3 and B-cell chronic lymphocytic leukemia: Remarkably, LAG-3 blockade, but not PD-1/PD-L1 axis blockade, enhances T-cell activation in CLL patients in vitro, in contrast with the findings of a study in which LAG3/PD-1 dual blockade increased the antileukemic immune response in Eμ-TCL1 murine models of CLL [49, 72].